Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer
September 28, 2022 - Cornerstone Pharmaceuticals, Inc. , a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the initiation of a Phase 1 clinical trial evaluating CPI-613 (devimistat) in combination with chemoradiation for the treatment of advanced pancreatic cancer.
- September 28, 2022 - Cornerstone Pharmaceuticals, Inc. , a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the initiation of a Phase 1 clinical trial evaluating CPI-613 (devimistat) in combination with chemoradiation for the treatment of advanced pancreatic cancer.
- The initiation of this Phase 1 trial is an important milestone for Cornerstone and demonstrates our continued commitment to exploring the potential of devimistat as a novel pancreatic cancer treatment, said Sanjeev Luther, President and CEO of Cornerstone Pharmaceuticals.
- The Phase 1 trial is an open-label, dose-escalation study being conducted at the Medical College of Wisconsin in Milwaukee.
- The combination of devimistat with chemoradiation could potentially lead to significant improvements in local control of pancreatic cancer with minimal added toxicity.